Drugs / Kreon
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT01641393 | Jun 2012 → Feb 2014 | exocrine pancreatic insufficiency | Forest Laboratories | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05480241 | May 2022 → Dec 2023 | acute pancreatitis, exocrine pancreatic insufficiency | Unidade Local de Saúde de Coimbra, EPE | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT01327703 Comparator | Apr 2011 → May 2012 | cystic fibrosis, exocrine pancreatic insufficiency | Forest Laboratories | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Kreon | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01327703 ↗ |
| Known as | Pancreatic Enzyme Replacement Therapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05480241 ↗ |
| Modality | Protein / enzyme biologic | “Kreon 25,000 is a PEP consisting of porcine-derived pancreatic enzymes.18” NCT01641393 ↗ |
| Route | Oral | “Kreon® 25,000 capsule will be given orally daily” NCT01327703 ↗ |